An Exploratory Study Comparing Two Nicotine Inhalers

NCT ID: NCT01478230

Last Updated: 2012-07-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-11-30
• Study Completion Date: 2011-12-31

Brief Summary

Subjects will be screened within 28 days before the first study treatment to confirm that they meet the requirements to participate in the trial. They will return to the site for two treatment visits, at least 12 hours each, and at least one day in between visits. At each visit treatment N1/3-I5 or Nicotine Inhaler 10 mg will be administered every hour for 11 hours. The investigator (or an appropriate delegate at the investigator site) will obtain informed consent from each subject. Blood samples will be drawn on a special schedule. The total predicted amount of blood sampled from each subject is 174 mL over the whole study. Subjects will be required to follow specific smoking and dietary restrictions and rate their urges to smoke, general liking of the product, and how easy the product is to use.

Detailed Description

Blood for pharmacokinetic analyses will be drawn prior to the first administration and immediately before administration at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 hours. Thereafter samples will be drawn at 5, 10, 15, 20, 25, 30, 45, and 60 minutes after the 11-hour administration. Easiness of use will be rated using an 8-grade ordered category scale at 10 minutes after the start of administrations at 3, 6, and 9 hours. Overall liking will be rated using an 8-grade ordered category scale at 12 hours. Urges to smoke will be rated on a 4-grade ordered category scale immediately before and at 15 minutes after the first administration, and as well as before and 15 minutes after the start of administrations at 3, 6, and 9 hours, and at 12 hours. Used cartridges will be collected. Pooled samples per subject and treatment will be analyzed to determine the amount of remaining nicotine. Tolerability of the treatments will be evaluated in terms of reported and observed adverse events (AE).

Since the primary objective is to compare steady-state nicotine pharmacokinetics of N1/3-I5 with that of Nicotine Inhaler 10 mg, this study will have a multiple-dose setting. A crossover design has been chosen for this study in order to allow within-subject comparisons of treatments. Healthy habituated adults smoking at least 10 cigarettes daily for at least one year preceding inclusion will be included in the study, since they are expected to tolerate the doses of nicotine that will be administered.

Conditions

Tobacco Dependence

Keywords

Pharmacokinetics

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

N1/3-I5

5 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits

Group Type: EXPERIMENTAL

Nicotine

Intervention Type: DRUG

Nicotine 5 mg Inhaler

NX-I10

10 mg Inhalation during 10 minutes every hour for 11 hours with a puff frequency of four puffs per minute, with a 36-hour washout between visits.

Group Type: ACTIVE_COMPARATOR

Nicotine

Intervention Type: DRUG

Nicotine 10 mg Inhaler

Interventions

Nicotine

Nicotine 5 mg Inhaler

Intervention Type: DRUG

Nicotine

Nicotine 10 mg Inhaler

Intervention Type: DRUG

Other Intervention Names

Not yet marketed; Not yet marketed

Eligibility Criteria

Inclusion Criteria

• Healthy (per protocol-specified parameters) male or female subjects between the ages of 19 and 50 years, inclusive.
• Smoking of at least 10 cigarettes daily during at least one year preceding inclusion.
• For females: Postmenopausal state or premenopausal/perimenopausal state with a protocol-specified effective means of contraception or declared absence of sexual contact with a male partner during the study.
• For males: No pregnant spouse or partner at screening and willingness to protect potential spouse or partner from becoming pregnant during the study.
• Body Mass Index (BMI) within protocol-specified parameters.
• A personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
• Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified in the protocol

• Males: Pregnant spouse or partner or no willingness to prevent conception in a spouse or partner.
• History of regular alcohol consumption outside the protocol-specified allowances.
• Treatment with an investigational drug within 3 months preceding the first dose of study treatment.
• Known sensitivity to heparin or history of heparin-induced thrombocytopenia.
• Pathological oral status interfering with normal muscular, sensory, or absorptive function of the oral cavity. Piercing of tongue and lips is considered to impair oral function.
• Relationship to persons involved directly with the conduct of the study, or their families.

Exclusion Criteria

• Evidence or history of an acute or chronic medical or psychiatric condition or allergy or laboratory abnormality, or of use of drugs that, in the judgment of the investigator or an authorized study physician, may increase the risk associated with study participation or interfere with the interpretability of study results.

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

McNeil AB

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Elisabeth Kruse, PhD

Role: STUDY_DIRECTOR

McNeil AB

Locations

McNeil AB Clinical Pharmacology R&D

Lund, , Sweden

Countries

Sweden

Other Identifiers

2011-002796-41

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

NICTDP0002

Identifier Type: -

Identifier Source: org_study_id